Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to PARN" (ENSG00000308270, LOC105371094) is an antisense long non-coding RNA (lncRNA) transcribed from the genomic region opposite the poly(A)-specific ribonuclease (PARN) gene. Antisense lncRNAs are a class of non-coding RNAs that typically regulate the expression, stability, or splicing of overlapping or neighboring genes through mechanisms such as transcriptional interference, the formation of double-stranded RNA, RNA masking, or recruitment of chromatin-modifying complexes[1][5]. While specific information about this antisense transcript's unique biological or disease roles is not reported, natural antisense transcripts frequently play regulatory roles in gene expression and may participate in fine-tuning responses to cellular stress or developmental cues. However, no direct disease association, drug interaction, or established biomarker or target use has been reported for this specific transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to PARN.